Home › Products › Infectious Disease › Spegra Tablet 30's
Spegra Tablet 30's
Salt Composition: DOLUTEGRAVIR,EMTRICITABINE,TENOFOVIR ALAFENAMIDE
- Manufacturer: EMCURE PHARMACEUTICALS LTD
- Pack Size: 30 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 50MG+200MG+25MG
- Prescription Required
- Storage: Store this medication below 30°C Protect the medicine from light and excessive moisture. Keep the medicine out of reach of children and pets If you forgot to take the tablet, take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
₹3165.00₹4521.50
Inclusive of all taxes
Product Introduction
Spegra Tablet contains the active ingredients dolutegravir, emtricitabine, and tenofovir alafenamide. It is a combination antiretroviral medication. Dolutegravir belongs to the class of integrase strand transfer inhibitors (INSTIs). Emtricitabine belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), and tenofovir alafenamide belongs to the class of nucleotide reverse transcriptase inhibitors (NtRTIs). It is used in combination with other medicines to treat human immunodeficiency virus (HIV-1) infection in adults and adolescents 12 years of age who weigh at least 35 kg. The combination is available as a single tablet regimen, simplifying treatment by reducing the number of pills patients must take daily. This convenience improves medication adherence, enabling individuals to consistently take their prescribed medication as scheduled. Do not take Spegra Tablet if you are allergic to it or its components. Patients should undergo regular testing for HIV infection whilst using this medicine. Missing a dose increases the risk of HIV infection. This medicine does not prevent other sexually transmitted infections (STIs). Patients should inform their physician if they have liver problems or liver disease, including hepatitis, kidney, and bone problems. This HIV medication is not recommended for children aged 11 years or under.
Uses
HIV infection
How it works
Spegra Tablet offers a highly effective and convenient treatment for HIV infection. It reduces viral load, maintains long-term viral suppression, and delays disease progression. A single-tablet regimen improves medication adherence. Additionally, it has an improved safety profile with a reduced risk of renal and bone toxicity.
How to Use
It is an orally available prescription drug. Your doctor will decide the dose and duration of Spegra Tablet based on the disease condition and other factors such as body weight and age. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water. If you have difficulty in swallowing the tablet whole, you can split it in half after consulting with your doctor.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Hepatitis B reactivation Increased risk of fracture Acute renal failure Common Headache Nausea Diarrhea Fatigue Insomnia
Expert Tips
If you are living with HIV or are at risk of contracting the virus, it is crucial to seek medical advice and follow a prescribed treatment plan. Antiretroviral therapy, such as the combination of Spegra Tablet, can significantly improve your health outcomes. However, it is essential to remember that medication adherence is key. Consistently taking your prescribed medication as directed by your healthcare provider and attending regular follow-up appointments will help ensure the effectiveness of the treatment and monitor your progress. Additionally, practicing safe sex, using clean needles, and taking preventive measures can significantly reduce the risk of HIV transmission. Remember to consult with healthcare professionals for personalized advice and guidance tailored to your specific needs and circumstances. Do not share needles or other items that may have blood or body fluids on them.
References
- Descovy 200 mg/25 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. Published April 2022. Accessed May 22, 2023. https://www.medicines.org.uk/emc/product/2108/smpc
- Emtricitabine / Tenofovir Alafenamide - Patient | NIH. clinicalinfo.hiv.gov. Published [February 27, 2023].[Accessed May 22, 2023]. https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/patient#dr1
- KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872.
- Gilead Sciences, Inc., US Food & Drug Administration, [Revised on Sep 2017] [Accessed on 22th Aug 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208215s005lbl.pdf
Safety Advice
Pregnancy: Consult your doctor There is limited information on the use of Spegra Tablet during pregnancy. Inform your physician if you are pregnant or planning to get pregnant during the treatment.
Lungs: Consult your doctor It is unknown whether Spegra Tablet is safe to administer to patients with lung diseases. Inform your physician if you have any lung diseases before initiating the therapy.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Spegra Tablet because the medicine passes into the breast milk in small amounts and may harm your baby. Do not breastfeed during the treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.